Acromegaly Treatment Market Exposure to varied markets,
capacity expansion & diversification key triggers Estimated By
Global
Players
Pfizer
Inc.,
Novartis
Pharma
AG,
GlaxoSmithKline plc, Midatech Pharma PLC
Acromegaly is a rare disorder caused due to the excess production of growth hormone by the
pituitary gland, affecting a patient’s physical appearance and internal organs. It is usually
caused by benign pituitary tumor (adenoma), however, in rare cases acromegaly symptoms can
be observed due to ineffective control of growth hormone-secreting cells by hypothalamus.
Abnormal enlargement of hands, arms, feet, legs, and head, and gradual changes in facial
features such as eye-brow, lower jaw, and nose are visible symptoms of this disorder. Untreated
acromegaly leads to serious and life threating complications such as cardiomyopathy and
ventricular arrhythmia. Blood test to measure levels of growth hormones or insulin-like growth
factor and imaging of tumors through MRI scan and CT scan are commonly used diagnostic
approaches to detect acromegaly. Some medications are 90% effective in shrinking tumor,
however, success rate of type of treatment varies based on age, health or medical history of
patients. According to the American Society of Clinical Oncology (ASCO), 14,230 individuals of
the U.S. were diagnosed with pituitary gland tumor in 2017, of which majority are benign
tumor. Furthermore, in 2017, the National Organization for Rare Disorders estimated the
prevalence rate of acromegaly as 50-70 person per million and 3 new cases occurs per million
every year, which is expected to increase the demand for acromegaly treatment market.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1477
Market Driver:
New drugs in the market widens the choice of therapies for doctors and patients. In 2017,
Midatech Pharma PLC submitted clinical trial application in human study of Q-Octreotide
(MTD201) programme in cancer and acromegaly, and now it has received oral confirmation
from Polish regulators for its approval in January 2018. Furthermore, Chiasma Inc’s new oral
maintenance therapy for acromegaly treatment named Mycapssa, which has completed an
international Phase 3 trial and further conducting an international Phase 3 clinical trial under a
protocol accepted by the European Medicines Agency (EMA) for adult patients with acromegaly